Seeking Alpha

William Blair has high hopes for Pharmacyclics' ibrutinib

  • William Blair is keeping expectations low for Pharmacyclics' (PCYC +1.4%) ibrutinib, saying only that the investigational BTK inhibitor "could become the largest product in hematology oncology history."
  • Cited in the report: The agent's potential in "almost all B-cell malignancies," its "best combined efficacy and safety profile," its first to market status, its potential to expand into more indications and move to frontline and maintenance settings from the relapsed/refractory setting, and a lack of competition.
  • PCYC initiated at Buy.
  • Price target is $143, representing a 20% upside from Monday's close.
Comments (1)
  • snakeriver83001
    , contributor
    Comments (3) | Send Message
     
    Just wait until the autoimmune indications are comprehended by the analysts!
    26 Sep 2013, 12:49 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs